Brooklyn Immunotherapeutics Inc (NASDAQ:BTX)

5.50
Delayed Data
As of 4:00pm ET
 -0.45 / -7.56%
Today’s Change
3.59
Today|||52-Week Range
80.67
+22.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$321.6M

Company Description

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.

Contact Information

Brooklyn ImmunoTherapeutics, Inc.
1040 1st Avenue
New York New York 10022
P:(212) 582-1199
Investor Relations:

Employees

Shareholders

Other institutional4.95%
Mutual fund holders4.84%
Individual stakeholders33.98%

Top Executives

Howard J. FederoffPresident, Chief Executive Officer & Director
Sandra GurrolaChief Financial Officers
Kevin A. D'AmourChief Scientific Officer
Jay SialChief Administrative & Scientific Officer
Roger SidhuChief Medical Officer